Last updated: May 23, 2026
Clorazepate dipotassium (a benzodiazepine) is an established, off-patent small-molecule product in most major markets. Public, drug-level sources do not show active late-stage (Phase 3) clinical development that would support a quantified “pipeline-driven” projection based on new pivotal trials. Market sizing and forecasting depend on generics’ price and distribution share, not on branded exclusivity or recent regulatory milestones.
What clinical trials exist for clorazepate dipotassium right now?
No current, clearly identifiable Phase 3 or registrational trial for clorazepate dipotassium is evidenced in public clinical-trial registries at the level needed for a dated, trial-specific update tied to regulatory approval timelines.
Are there ongoing Phase 1 or bioequivalence studies?
Open-label or bioequivalence work may exist intermittently for generic submissions, but drug-level, submission-linked studies do not map cleanly to a “clinical trials update” narrative with market-moving endpoints (eg, superiority/effectiveness trials). This keeps the pipeline projection anchored to generic competition rather than to new clinical evidence.
What endpoints are typically targeted if trials occur?
When trials occur for benzodiazepines at the generic level, endpoints usually center on:
- Pharmacokinetics and bioequivalence (rate and extent of absorption)
- Safety/tolerability in short windows
- Assay and dissolution comparability for solid oral dosage forms
How big is the clorazepate dipotassium market and what is the buyer profile?
The practical market for clorazepate dipotassium is dominated by generic supply. Demand is driven by:
- Chronic management of anxiety symptoms (where benzodiazepines are used)
- Seizure/convulsive disorder adjunct use in certain practice patterns
- Long-term prescribing habits and formulary positioning
- Substitution by alternatives when payers or guidelines restrict benzodiazepine use
Which geographies matter most commercially?
Commercial exposure concentrates in markets with:
- Large generic distribution networks
- Stable outpatient and neurologic/psychiatric prescribing volumes
- Generic pricing tolerance in formularies
What reimbursed channels drive sales?
- Retail pharmacy reimbursement for outpatient anxiety/benzodiazepine use
- Hospital outpatient and neurology workflows for seizure-related adjunct dosing
What is the competitive landscape for clorazepate dipotassium generics?
Competitive intensity is high because the product is mature and genericized. Market share is driven by:
- Number and footprint of ANDA-approved generic manufacturers
- Pricing and rebate structures
- Availability by strength (eg, typical marketed strengths) and dosage form (oral tablets)
- Formulary tiers and substitution rules at the pharmacy counter
How does competitive intensity show up in pricing?
For off-patent benzodiazepines:
- Pricing typically compresses quickly after additional entrants
- Consolidation around a smaller set of large distributors and high-turn SKUs is common
- Launches usually show volume capture rather than margin expansion
When does clorazepate dipotassium lose exclusivity and patent protection?
Clorazepate dipotassium is widely treated as off-patent. As a result:
- Launch windows are not governed by a single branded exclusivity end date
- Generic entry is constrained primarily by remaining formulation-specific patents (if any) and by regulatory readiness (ANDA status, quality approvals)
Do any meaningful regulatory exclusivities apply?
For mature small molecules:
- Relying on new regulatory exclusivity to time entry is typically not applicable unless a new NDA or 505(b)(2) pathway created exclusivities tied to reformulation or new indication
- Public sources do not support a current, drug-level exclusivity timeline for a brand-based renewal that would change forecasting materially
What patents protect clorazepate dipotassium and how strong is the estate?
A drug-level patent estate assessment for clorazepate dipotassium cannot be completed to the actionable standard required for litigation and licensing decisions using public information alone, because:
- The product’s primary protection has largely matured
- Remaining protections, if any, are likely to be narrow (formulation, manufacturing process, or specific methods of use)
- Drug-level patent lists must be tied to an identified Orange Book record for the exact NDA/strength/dosage form to avoid mismapping coverage
What is the Orange Book status of clorazepate dipotassium?
A complete Orange Book status requires identifying the specific listed NDA numbers and associated listed patents per dosage form and strength. That structured listing is not available in the information provided here at the level needed to deliver a correct status table.
How many ANDAs exist for clorazepate dipotassium and what is the generic launch risk?
Generic launch risk for clorazepate dipotassium is generally low in the sense that:
- Market entry has already occurred historically
- Remaining barriers tend to be procedural (ANDA approval readiness, stability/CMC) or narrow patent coverage
The “risk” that matters for new entrants is less about broad patent injunction probability and more about:
- The presence of any unexpired, narrowly relevant listed patents for particular strengths
- Litigation posture (if a Paragraph IV challenge exists in the NDA’s ANDA cohort)
- Supply-chain readiness (raw material sourcing and scale-up)
Has any Paragraph IV litigation been filed for clorazepate dipotassium?
No drug-specific, dossier-ready Paragraph IV litigation record is available here to enumerate case numbers, filing dates, and settlement terms. For market projections, this means the baseline assumption is ongoing generic access rather than a pending injunction-driven disruption.
How would a biosimilar or biologics comparison apply here?
Clorazepate dipotassium is a small molecule and is not associated with biosimilar pathways. Any “biosimilar risk” framing does not apply.
What formulation patents could matter for new clorazepate dipotassium launches?
If formulation differentiation exists in practice, it typically targets:
- Modified-release or controlled-release profiles (if present)
- Bioavailability improvements via salt form characteristics, excipient systems, or manufacturing controls
- Stability and shelf-life improvements that reduce recalls and improve supply continuity
For market entrants, formulation-related differentiation can protect against immediate label-level substitution only if linked to listed patents and supported by FDA labeling differences, which is not evidenced here in a way that supports a quantified projection.
Commercial forecast: base case, bull case, bear case
Because clorazepate dipotassium is mature and genericized, forecasting is best framed around generic supply, pricing cycles, and guideline/payer restrictions rather than on new clinical readouts.
Base case (most probable)
- Volume remains stable-to-slightly down in mature markets due to prescribing substitution toward other benzodiazepines or non-benzodiazepine anxiolytics in some formularies
- Pricing drifts downward or stabilizes at low levels depending on number of active suppliers
- Revenue growth is limited and tied to demographic and utilization shifts rather than pipeline catalysts
Bear case
- Additional generic entrants further compress pricing
- Restrictive formulary policies reduce benzodiazepine use for certain indications
- Supply disruptions in common APIs or contract manufacturing reduce fill rates
Bull case
- A supplier consolidation improves supply reliability and reduces price volatility
- Increased utilization in neurology adjunct settings offsets prescribing substitution
- Stable formulary placement with favorable pharmacy reimbursement
Key timing markers to watch (non-pipeline drivers)
Even without an identifiable Phase 3 program, market changes often cluster around:
- ANDA approvals and new label/strength availability (supply increases)
- Patent settlements that trigger multi-SKU entry waves
- Formulary policy updates by PBMs
- FDA labeling changes that can influence prescribing
What market actions should a business take given the clinical and regulatory posture?
- Treat clinical development as non-catalytic for near-term revenue projection unless a new registrational program appears in public records
- Model revenue on generic lifecycle dynamics: entrant count, net price, and retention in formulary tiers
- Use strength- and dosage-form granularity in any entry plan, because residual narrow patents, if any, are typically tied to particular listings
Key Takeaways
- Clorazepate dipotassium is mature and primarily contested in the generic market, not shaped by an active late-stage clinical pipeline.
- Clinical trial updates do not provide a registrational catalyst timeline that would change exclusivity-based forecasting.
- Market projections should emphasize generic pricing and supply dynamics, not branded patent cliffs or Paragraph IV waves.
- A complete patent/Orange Book status and litigation map cannot be produced here to an actionable standard because NDA/Orange Book listing identifiers and drug-level patent tables are not provided.
FAQs
1) Are there any ongoing Phase 3 trials for clorazepate dipotassium that could expand indications?
No public, drug-level Phase 3 registrational program is evidenced here.
2) What drives clorazepate dipotassium revenue if clinical pipeline catalysts are absent?
Generic pricing, supply continuity, and formulary placement.
3) Can a new formulation of clorazepate dipotassium create new exclusivity?
Only if it triggers FDA exclusivity via a pathway with new clinical/CMC differentiation and linked statutory exclusivities; no such program is evidenced here.
4) What litigation risk matters for new generic entrants?
Any narrow, unexpired listed patents tied to specific strengths/dosage forms and the presence or absence of Paragraph IV challenges for those listings.
5) Does biosimilar competition affect clorazepate dipotassium?
No; it is a small molecule.
References
No sources were provided or identifiable in the prompt with sufficient detail to cite accurately in APA format.
